Across the sector, companies are aggressively evaluating entry points, API partnerships, and dosage forms to capture this massive TAM 7/n: Bottom Line : Players will be benefited who successfully backward integrate their supply chains, invest heavily in R&D for complex/high-potent molecules, and maintain the immaculate regulatory track records required to win long-term Western CDMO contracts
Retrieved from Eli Lilly-d
Wong HJ, Sim B, Teo YH, Teo YN, Chan MY, Yeo LLL, et al
Zepbound (2023) was similarly reviewed in six months, partly because tirzepatide's safety was already established through Mounjaro's prior approval for diabetes
The Potential of GLP-1 Therapies One of the most promising advances in addressing these issues is GLP-1 therapy